Similar results have also been reported by Brauer et al. that the use of DPP4 inhibitors and/or GLP-1 RA is associated with a lower rate of PD compared to the use of other oral antidiabetic drugs [139]. This evidence concerns the gene DPP4 and Parkinson disease.